Wockhardt (Rs. 276.00) (Code : 532300)
:Wockhardt is a global pharma & biotech company, with 14 manufacturing plants in India, UK, Ireland, France and U. S. The company is divesting its Nutritutional business to Danone for US $ 355 million. Infact, this was agreed in the first week of August 2011 when $/rupee parity was at 45, which is now at 53. So, company will
realize Rs. 1,850 crores now, instead of Rs. 1,600 crores estimated earlier. The company has also been improving its financial performance.For 6 months ending 30-09-11, total income of the company was placed at Rs. 2,163 crores (Rs. 1,862 cr. in corresponding period of the previous year) with profit after tax of Rs. 317 crores against net loss of Rs. 213 crores.The company is facing fresh litigations with FCCB Holders, in Bombay High Court, hearing of which is scheduled on 13th January, 2012. This is likely to get resolved and thereafter, Nutrition Business will get divested by the company. On divesting the Nutrition business, this will get vastly reduced, which can make the company to come back on tracks.Present equity of the company is at Rs. 55
crores, with promoters’ stake at 73.64%, Inst. Investors holding 7.82% and HNIs and Bodies Corporate holding 8.28%, with about 10% held by the public. The stock is trading at Rs. 281 which is very attractive. Watch out the court verdict on 13th January and then buy for the year.
:Wockhardt is a global pharma & biotech company, with 14 manufacturing plants in India, UK, Ireland, France and U. S. The company is divesting its Nutritutional business to Danone for US $ 355 million. Infact, this was agreed in the first week of August 2011 when $/rupee parity was at 45, which is now at 53. So, company will
realize Rs. 1,850 crores now, instead of Rs. 1,600 crores estimated earlier. The company has also been improving its financial performance.For 6 months ending 30-09-11, total income of the company was placed at Rs. 2,163 crores (Rs. 1,862 cr. in corresponding period of the previous year) with profit after tax of Rs. 317 crores against net loss of Rs. 213 crores.The company is facing fresh litigations with FCCB Holders, in Bombay High Court, hearing of which is scheduled on 13th January, 2012. This is likely to get resolved and thereafter, Nutrition Business will get divested by the company. On divesting the Nutrition business, this will get vastly reduced, which can make the company to come back on tracks.Present equity of the company is at Rs. 55
crores, with promoters’ stake at 73.64%, Inst. Investors holding 7.82% and HNIs and Bodies Corporate holding 8.28%, with about 10% held by the public. The stock is trading at Rs. 281 which is very attractive. Watch out the court verdict on 13th January and then buy for the year.
HCL Technologies (Rs. 388.00) (Code : 532281) :
HCL Tech is one of the leading IT company in the country. The company is focusing on developing capabilities in enterprise mobility and analytics to complement existing offerings. This could improve margins on the back of an improving employee pyramid and scale efficiencies. it has been selected by AstraZeneca to manage its data centres across 60 locations, globally. This indicates deal traction in infrastructure management services (IMS) is strong. It also indicates HCL is better placed to get a higher market share in this space, as clients close their budgets. The stock has been consolidating at around Rs. 380-390 level since last one month. From here on, there is very less downside risk. It is right time to buy the stock as the result season is around the corner. It will zoom after results. As the rupee sliding is continue, the stock will get more push up. Buy immediately.
HCL Tech is one of the leading IT company in the country. The company is focusing on developing capabilities in enterprise mobility and analytics to complement existing offerings. This could improve margins on the back of an improving employee pyramid and scale efficiencies. it has been selected by AstraZeneca to manage its data centres across 60 locations, globally. This indicates deal traction in infrastructure management services (IMS) is strong. It also indicates HCL is better placed to get a higher market share in this space, as clients close their budgets. The stock has been consolidating at around Rs. 380-390 level since last one month. From here on, there is very less downside risk. It is right time to buy the stock as the result season is around the corner. It will zoom after results. As the rupee sliding is continue, the stock will get more push up. Buy immediately.
Gitanjali Gems (Rs. 302.00) (Code : 532715) :
Gitanjali Gems is in the business of Jems and Jewellery. It has various companies under its wing, namely – Gili, Asmi, Nakshatra, Sangini and the like, apart from jewelleries, Gitanjali Gems also manufactures watches. Its mostly caters to the US in foreign markets. It was also involved in a number of acquisitions of foreign companies in the last few years. It registered net sales of 3167.6 crores, for the quarter ended September, 2011, indicating a 26.2 percent growth over the last year. It also registered a net gain of 132.2 crores in the same quarter. This growth has been contributed to better consumer reaction from Tier II and Tier III cities in India. Brand name is also a strong point of the company and, hence, the growth. Recently, Gitanjali, through its subsidiary, has acquired 100% stake in Crown Aim Ltd. Crown Aim is a Hong Kong based company engaged in jewellery distribution to China, Japan, USA, middle east and Europe. In December, the BSE has included Gitanjali Gems into its BSE-200 index. The stock has corrected in recent months. Grab this opportunity. To reduce your risk, buy in two phase.
Gitanjali Gems is in the business of Jems and Jewellery. It has various companies under its wing, namely – Gili, Asmi, Nakshatra, Sangini and the like, apart from jewelleries, Gitanjali Gems also manufactures watches. Its mostly caters to the US in foreign markets. It was also involved in a number of acquisitions of foreign companies in the last few years. It registered net sales of 3167.6 crores, for the quarter ended September, 2011, indicating a 26.2 percent growth over the last year. It also registered a net gain of 132.2 crores in the same quarter. This growth has been contributed to better consumer reaction from Tier II and Tier III cities in India. Brand name is also a strong point of the company and, hence, the growth. Recently, Gitanjali, through its subsidiary, has acquired 100% stake in Crown Aim Ltd. Crown Aim is a Hong Kong based company engaged in jewellery distribution to China, Japan, USA, middle east and Europe. In December, the BSE has included Gitanjali Gems into its BSE-200 index. The stock has corrected in recent months. Grab this opportunity. To reduce your risk, buy in two phase.
No comments:
Post a Comment